PR95681

IRVINE, Calif., April 27, 2022 /PRNewswire=KYODO JBN/ --

Zymo Research and Star Array today announced Zymo Research's strategic

investment to acquire an interest in Star Array, a privately owned, biomedical

technology company based in Singapore. The investment allows Zymo Research and

Star Array to combine Zymo Research's nucleic acid purification and assay

technologies with Star Array's engineering and automation expertise to expand

into emerging For Research Use Only (FRUO) and diagnostic markets including

Point-of-Care testing (POCT).

Photo – https://mma.prnewswire.com/media/1805123/Zymo_Research_Star_Array.jpg

Logo – https://mma.prnewswire.com/media/364743/Zymo_Research_Corp_Logo.jpg

Star Array's focus has been on the development of an automated (cassette-based)

nucleic acid purification system coupled with its superfast nucleic acid

amplification technology. It manufactures and markets various genetic analyzers

including its premier product, XDive (TM), a superfast qPCR platform, with

related kits and software. During the COVID-19 outbreak, Star Array developed a

test for SARS-CoV-2 detection utilizing its XDive (TM) system. The entire

process from sample-to-answer takes less than 45 minutes and the system can be

used in any clinical environment. Star Array is currently working through the

Emergency Use Authorization (EUA) process with the U.S. Food and Drug

Administration (FDA) through the National Institutes of Health (NIH) Rapid

Acceleration of Diagnostics (RADx (R)) program.

Zymo Research, since its inception in 1994, is well known for its DNA/RNA

extraction and assay technologies. Its goal has been to develop more efficient

sample collection kits and devices that simplify and reduce the time needed to

isolate nucleic acids in the laboratory. Zymo Research will be partnering with

Star Array to develop ready-made cassettes containing the necessary reagents

for Star Array's COVID-19 test kit as well as future POCT.

"Star Array's powerful PCR instrumentation places them at the forefront of PCR

technology with their XDive (TM) PCR system that can complete a typical

40-cycle multiplex qPCR run in 5-7 minutes. When coupled with Star Array's

system, Zymo Research's DNA/RNA purification reagents and nucleic acid-based

assays will facilitate a straightforward Sample-In/Answer-Out workflow. Through

our investment in Star Array we will develop products targeting POCT in the

global marketplace," said Marc Van Eden, Vice President of Business Development

at Zymo Research.

"Zymo Research and Star Array have both built businesses at the intersection of

science and technology and we share a vision of ultrafast PCR technology that

will enable POC PCR tests to be analyzed in just minutes in doctor's offices,

laboratories, and hospitals. Together we strive to build even more POCT

products in the future," said Dr. Yanhui Liu, Vice President of Star Array Pte.

Ltd.

To learn more about Zymo Research's DNA/RNA extraction and assay technologies

visit their website (https://c212.net/c/link/?t=0&l=en&o=3516713-1&h=3299386075&u=https%3A%2F%2Fwww.zymoresearch.com%2Fpages%2Fall-products&a=website). For more information about Star Array's technology, click here:

https://www.star-array.com/research-tools.

About Zymo Research Corp.

Zymo Research is a privately owned company that has been serving the scientific

and diagnostics community with state-of-the-art molecular biology tools since

1994. The company's vision "The Beauty of Science is to Make Things Simple" is

reflected in all of its products, from epigenetics to DNA/RNA purification

technologies. Historically recognized as the leader in epigenetics, Zymo

Research is breaking boundaries with novel solutions for sample collection,

microbiomic measurements, diagnostic devices, and Next-Generation Sequencing

(NGS) technologies that are high quality and simple to use.

Follow Zymo Research on Facebook (https://c212.net/c/link/?t=0&l=en&o=3516713-1&h=2745015097&u=https%3A%2F%2Fwww.facebook.com%2Fzymoresearch&a=Facebook),

LinkedIn (https://c212.net/c/link/?t=0&l=en&o=3516713-1&h=95365927&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fzymo-research-corp%2F&a=LinkedIn), Twitter (https://c212.net/c/link/?t=0&l=en&o=3516713-1&h=3320357963&u=https%3A%2F%2Ftwitter.com%2FZymoResearch&a=Twitter), and

Instagram (https://c212.net/c/link/?t=0&l=en&o=3516713-1&h=3330174717&u=https%3A%2F%2Fwww.instagram.com%2Fzymoresearch%2F&a=Instagram).

About Star Array Pte Ltd

Star Array is a leading developer of super-fast on-site genetic testing based

on novel integrated sample preparation and qPCR processes. The company focuses

on superfast nucleic acid amplification and extraction technologies. The demand

for rapid response time has led Star Array to introduce superfast genetic

testing for on-site precision treatment in doctor's offices and routine

laboratory testing in hospitals. Star Array is headquartered in Singapore.

Contact Star Array at https://www.star-array.com.

SOURCE: Zymo Research Corp.

CONTACT: Marketing Department, Zymo Research Corp., 949.679.1190,

marketing@zymoresearch.com